Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients

Lamivudine, telbivudine, and entecavir are the first-line drugs covered by the Taiwan National Health Insurance as 3-year treatments for patients with chronic hepatitis B virus (HBV), but the optimal treatment duration of each remains unclear. We aimed to detect HBV treatment-cessation durability, a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Ching-Chung Lin, Ming-Jong Bair, Chih-Jen Chen, Keng-Han Lee, Ming-Jen Chen, Chia-Yuan Liu, Chen-Wang Chang, Kuang-Chun Hu, Tai-Cherng Liou, Shee-Chan Lin, Horng-Yuan Wang, Cheng-Hsin Chu, Shou-Chuan Shih, Tsang-En Wang
Format: Artigo
Jezik:Inglês
Izdano: Wiley 2016-01-01
Serija:Kaohsiung Journal of Medical Sciences
Teme:
Alanine aminotransferase
Entecavir
Hepatitis B virus
Lamivudine
Telbivudine
Online dostop:http://www.sciencedirect.com/science/article/pii/S1607551X15002582
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki